SCHEMBL15007948

SCHEMBL15007948

Cc1ccc(-c2cnc(C(C)(C)C)[nH]2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 6/20 0.54
SSTR3 P32745 3/20 0.48
KCNH2 Q12809 3/20 0.48
SCN1A P35498 1/20 0.48
SCN5A Q14524 1/20 0.48
SCN9A Q15858 1/20 0.48
SCN2A Q99250 1/20 0.48
SCN8A Q9UQD0 1/20 0.48
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
SMPD3 Q9NY59 1/20 0.43
NPC1 O15118 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5949923 0.85 SCN10A (0.54) SCN10AKCNH2SCN1ASCN5ASCN9A
SCHEMBL12549011 0.84 SCN10A (0.76) SCN10AKCNH2SCN1ASCN5ASCN9A
SCHEMBL17066290 0.84 SCN10A (0.53) SCN10AKCNH2SCN1ASCN5ASCN9A
SCHEMBL1690431 0.83 SCN2A (0.55) SCN10AKCNH2SCN1ASCN5ASCN9A
SCHEMBL15746250 0.82 SCN10A (0.47) SCN10ASSTR3KCNH2SCN1ASCN5A
SCHEMBL18506235 0.81 SCN10A (0.54) SCN10AKCNH2SCN1ASCN5ASCN9A
SCHEMBL22399118 0.78 CNR1 (0.50) SCN10ASSTR3KCNH2SCN1ASCN5A
SCHEMBL17066291 0.77 SCN10A (0.47) SCN10AKCNH2SCN1ASCN5ASCN9A
SCHEMBL25818969 0.77 SCN10A (0.79) SCN10AKCNH2SCN1ASCN5ASCN9A
SCHEMBL15747113 0.76 CYP2A6 (0.56) SSTR3SCN2AMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10766912-B2 Silicon-containing compound for resistance to hepatitis C virus infection CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-09-08 US disclosed
US-9527846-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 US disclosed
US-9527846-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 US disclosed
US-9527846-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 US disclosed
EP-2788349-B1 KINASE INHIBITORS CHIESI FARMA SPA (IT) 2016-10-26 EP disclosed
EP-2788349-B1 KINASE INHIBITORS CHIESI FARMA SPA (IT) 2016-10-26 EP disclosed
US-20160229852-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2016-08-11 US disclosed
US-20160229852-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2016-08-11 US disclosed
US-20160229852-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2016-08-11 US disclosed
US-9315503-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-04-19 US disclosed
US-20150080375-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-03-19 US disclosed
US-8907094-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2014-12-09 US disclosed
US-8907094-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2014-12-09 US disclosed
US-8907094-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2014-12-09 US disclosed
US-20140323470-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-10-30 US disclosed
US-20140323470-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-10-30 US disclosed
US-20140323470-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-10-30 US disclosed
US-20130150343-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-13 US disclosed
US-20130150343-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-13 US disclosed
US-20130150343-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229852-A1 KINASE INHIBITORS MAPK1, MAP3K1, MAPK6 SCN10A 3341/4885SSTR3 4005/4885KCNH2 2721/4885
US-20150080375-A1 KINASE INHIBITORS MAPK1, MAP3K1, MAPK6 SCN10A 3341/4885SSTR3 4005/4885KCNH2 2721/4885
US-20140323470-A1 KINASE INHIBITORS MAPK1, MAP3K1, MAPK6 SCN10A 3341/4885SSTR3 4005/4885KCNH2 2721/4885
US-10766912-B2 Silicon-containing compound for resistance to hepatitis C virus infection SLC11A2, SLC10A1, SLC39A11 SCN10A 1174/4885SSTR3 171/4885KCNH2 2517/4885
US-20130150343-A1 KINASE INHIBITORS MAPK1, MAP3K1, MAPK6 SCN10A 3341/4885SSTR3 4005/4885KCNH2 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.